ArticleDrugs in R&D2026

Response to "Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema".

Imtiaz A SamjooPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.